glp-1 average weight loss has changed the conversation around loss—but it's important to understand what it can and cannot do. It's not the right choice for everyone, and it's not a replacement for healthy GLP-1 Weight Loss Medication Treatment

Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks

This report provides an in-depth analysis of the Glutathione Supplements market in the World, including market size, structure, key trends, and forecast

Ideal for Dark Spots: If you struggle with areas of very dark skin or stubborn dark spots, this injection can help even out your skin tone

E.KorneevD

www.tradingstandards.uk Please contact CTSI Press Office: [email protected] for any queries.